Tag: Drug Development
David Epstein launches new cancer startup after Novartis and Seagen career
David Epstein, who previously served as the CEO of Seagen, has launched a new cancer startup called Ottimo Pharma. The company aims to develop a drug that targets two proteins, PD-1 and VEGF, in...
Seaport Therapeutics Secures $225 Million to Advance Neuroscience Innovation in the ‘Golden Age’
Seaport Therapeutics, a new biotech startup led by the team from Karuna Therapeutics, has successfully secured an additional $225 million in funding just half a year after its last fundraising effort. The Series B...
RSV Prophylactic Beyfortus: Potential Competitors and Market Trends
Alnylam Pharmaceuticals, led by CEO Yvonne Greenstreet, is making strides in expanding the use of its RNA-based gene-silencing heart drug, vutrisiran. The drug has shown promising results in reducing the risk of death and...
FDA Rejects MDMA and Nasal Spray for Allergic Reactions: Pharmalittle Update
Good morning everyone, hope you had a restful weekend and are ready to tackle the new week ahead. As we sip on some refreshing blueberry cobbler, let's dive into some interesting updates. The U.S....
Pfizer CEO’s Vision for Leading Cancer and Obesity Treatments
Albert Bourla, the CEO of Pfizer, is looking to shift the focus of the company from its successful COVID-19 vaccine and antiviral Paxlovid to new investments in drugs for cancer and obesity. While Pfizer's...
New Title: Soft-Tissue Cancer Drug Approval and Zepbound Shortage Update: Pharmalittle News
Good morning, this is Jonathan Wosen, reporting on the latest news in the biotech and life sciences world. The FDA has recently approved a new treatment for a rare soft tissue cancer. This cutting-edge...